Ken Griffin Rigel Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $176,288 - $247,118	-157,400 Reduced 64.8%	85,500 $126,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $792 - $1,716	1,100 Added 0.45%	242,900 $352,000
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $16,478 - $21,406	15,400 Added 6.8%	241,800 $261,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $15,344 - $24,934	13,700 Added 6.44%	226,400 $292,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $32,000 - $51,200	25,600 Added 13.68%	212,700 $280,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $39,664 - $704,480	59,200 Added 46.29%	187,100 $280,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $14,630 - $162,260	13,300 Added 11.61%	127,900 $151,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.